Form 4: Mira Pharmaceuticals Grants Stock Options to Edward MacPherson

Mira Pharmaceuticals has granted 25,000 stock options to Edward MacPherson, vesting in two equal tranches over the next year.

Summary

• Mira Pharmaceuticals granted 25,000 stock options to Edward MacPherson on December 6, 2024.
• The exercise price for these options is $1.19 per share, which was the closing price of the company's common stock on the grant date.
• The options were granted under the company's 2022 Omnibus Incentive Plan.
• 50% of the options will vest on the six-month anniversary of the grant date, and the remaining 50% will vest on the one-year anniversary.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for employee motivation and alignment with company goals. There are no negative implications.

Positives

• The stock options provide an incentive for Edward MacPherson, aligning his interests with the company's performance.
• The vesting schedule encourages long-term commitment from the recipient.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key personnel and align their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation in the pharmaceutical industry, often used to attract and retain talent.
• Vesting schedules, such as the six and twelve month vesting periods in this case, are typical for stock option grants.
• The exercise price being set at the closing price on the grant date is also a common practice.

Stakeholder Impact

• The stock option grant may have a positive impact on employee morale and motivation.
• Shareholders may view this as a positive step in aligning management's interests with the company's performance.

Key Dates

Keywords

stock options, equity compensation, vesting, Mira Pharmaceuticals, Edward MacPherson, incentive plan